The 36-month beta value for DYN is at 1.16. Analysts have varying views on the stock, with 8 analysts rating it as a “buy,” 7 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for DYN is 85.23M, and currently, shorts hold a 29.95% of that float. The average trading volume for DYN on June 17, 2025 was 2.50M shares.
DYN) stock’s latest price update
The stock price of Dyne Therapeutics Inc (NASDAQ: DYN) has dropped by -4.09 compared to previous close of 14.41. Despite this, the company has seen a fall of -4.03% in its stock price over the last five trading days. globenewswire.com reported 2025-06-16 that WALTHAM, Mass., June 16, 2025 (GLOBE NEWSWIRE) — Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage neuromuscular disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced it plans to provide an update on DYNE-101 in myotonic dystrophy type 1 (DM1) tomorrow, June 17, 2025, and to host a webcast at 8:00 a.m. ET. The company intends to issue a press release prior to the start of the event.
DYN’s Market Performance
Dyne Therapeutics Inc (DYN) has seen a -4.03% fall in stock performance for the week, with a 17.72% gain in the past month and a 12.27% surge in the past quarter. The volatility ratio for the week is 1.73%, and the volatility levels for the past 30 days are at 3.26% for DYN. The simple moving average for the past 20 days is 5.69% for DYN’s stock, with a -33.54% simple moving average for the past 200 days.
Analysts’ Opinion of DYN
Many brokerage firms have already submitted their reports for DYN stocks, with Raymond James repeating the rating for DYN by listing it as a “Outperform.” The predicted price for DYN in the upcoming period, according to Raymond James is $37 based on the research report published on June 11, 2025 of the current year 2025.
Oppenheimer, on the other hand, stated in their research note that they expect to see DYN reach a price target of $34. The rating they have provided for DYN stocks is “Outperform” according to the report published on June 02nd, 2025.
Evercore ISI gave a rating of “Outperform” to DYN, setting the target price at $46 in the report published on May 29th of the current year.
DYN Trading at 23.02% from the 50-Day Moving Average
After a stumble in the market that brought DYN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -70.87% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DYN starting from Scalzo Richard William, who proposed sale 1,330 shares at the price of $14.75 back on Jun 11 ’25. After this action, Scalzo Richard William now owns shares of Dyne Therapeutics Inc, valued at $19,619 using the latest closing price.
Beskrovnaya Oxana, the Officer of Dyne Therapeutics Inc, proposed sale 2,132 shares at $14.75 during a trade that took place back on Jun 11 ’25, which means that Beskrovnaya Oxana is holding shares at $31,449 based on the most recent closing price.
Stock Fundamentals for DYN
The total capital return value is set at -0.58. Equity return is now at value -64.01, with -59.05 for asset returns.
Based on Dyne Therapeutics Inc (DYN), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -13.7.
Currently, EBITDA for the company is -315.18 million with net debt to EBITDA at 1.13. The liquidity ratio also appears to be rather interesting for investors as it stands at 20.35.
Conclusion
In conclusion, Dyne Therapeutics Inc (DYN) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
